Two-year outcomes of episcleral brachytherapy adjunct to anti-VEGF therapy for treatment-resistant nAMD.

MLA

Chhablani, Jay, et al. “Two-Year Outcomes of Episcleral Brachytherapy Adjunct to Anti-VEGF Therapy for Treatment-Resistant NAMD.” Graefe’s Archive for Clinical and Experimental Ophthalmology = Albrecht von Graefes Archiv Fur Klinische Und Experimentelle Ophthalmologie, vol. 260, no. 12, Dec. 2022, pp. 3791–98. EBSCOhost, https://doi.org/10.1007/s00417-022-05736-0.

APA

Chhablani, J., Jager, R., Ong, J., Lohrenz, R., Hamilton, R. J., Stea, B., Drew, M., & Kokame, G. (2022). Two-year outcomes of episcleral brachytherapy adjunct to anti-VEGF therapy for treatment-resistant nAMD. Graefe’s Archive for Clinical and Experimental Ophthalmology = Albrecht von Graefes Archiv Fur Klinische Und Experimentelle Ophthalmologie, 260(12), 3791–3798. https://doi.org/10.1007/s00417-022-05736-0

Chicago

Chhablani, Jay, Rama Jager, Joshua Ong, Ryan Lohrenz, Russell J Hamilton, Baldassare Stea, Mary Drew, and Gregg Kokame. 2022. “Two-Year Outcomes of Episcleral Brachytherapy Adjunct to Anti-VEGF Therapy for Treatment-Resistant NAMD.” Graefe’s Archive for Clinical and Experimental Ophthalmology = Albrecht von Graefes Archiv Fur Klinische Und Experimentelle Ophthalmologie 260 (12): 3791–98. doi:10.1007/s00417-022-05736-0.